Related Experiment Video
Updated: Oct 5, 2025
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
Published on: January 6, 2012
Tetramethylpyrazine Retards the Progression and Fibrogenesis of Endometriosis
Shenghui Huang1, Fengyi Xiao2, Sun-Wei Guo3,4
1Department of Gynecology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Abstract:
The development of more efficacious, non-hormonal therapeutics for endometriosis is still an unmet medical need begging to be fulfilled. Growing evidence indicates that endometriotic lesions are wounds undergoing repeated tissue injury and repair, and, as such, platelets play an important role in lesional progression. Tetramethylpyrazine (TMP), a compound derived from a herb that has been used for thousands of years to combat "blood stasis" in traditional Chinese medicine, is a prescription drug in China for the treatment of cerebrovascular disorders. We tested the hypothesis that TMP can decelerate lesional progression through arresting epithelial-mesenchymal transition (EMT), fibroblast-to-myofibroblast transdifferentiation (FMT), and fibrogenesis. We found in our in vitro experiments that TMP treatment suppresses platelet-induced EMT, FMT, cellular contractility, and collagen production in a concentration-dependent manner. We also showed that in a mouse model of endometriosis, treatment with TMP significantly reduced lesion weight and the extent of lesional fibrosis and improved hyperalgesia, mostly likely through the reduction of lesional aggregation of platelets and the lesional expression of markers of EMT, FMT, and fibrogenesis. In light of our results and in view of its excellent safety profiles, TMP appears to be a promising drug candidate for treating endometriosis.
Insights
Tetramethylpyrazine (TMP) shows promise as a non-hormonal endometriosis treatment. This compound reduced lesion progression, fibrosis, and pain in preclinical models by inhibiting key cellular processes.
Area of Science:
- Reproductive Medicine
- Pharmacology
- Cell Biology
Background:
- Endometriosis lacks effective non-hormonal treatments, representing a significant unmet medical need.
- Platelets are implicated in the progression of endometriotic lesions, which resemble chronic wounds.
- Tetramethylpyrazine (TMP), a traditional Chinese medicine compound, is approved for cerebrovascular disorders.
Purpose of the Study:
- To investigate the potential of Tetramethylpyrazine (TMP) in decelerating endometriosis progression.
- To determine if TMP can inhibit epithelial-mesenchymal transition (EMT), fibroblast-to-myofibroblast transdifferentiation (FMT), and fibrogenesis in endometriosis.
Main Methods:
- In vitro experiments assessed TMP's effect on platelet-induced EMT, FMT, cellular contractility, and collagen production.
- A mouse model of endometriosis was used to evaluate TMP's impact on lesion weight, fibrosis, and hyperalgesia.
Main Results:
- TMP suppressed platelet-induced EMT, FMT, cellular contractility, and collagen production in a dose-dependent manner.
- In vivo, TMP significantly reduced lesion weight, fibrosis, and hyperalgesia in a mouse model.
- These effects were associated with reduced platelet aggregation and suppressed markers of EMT, FMT, and fibrogenesis in lesions.
Conclusions:
- Tetramethylpyrazine (TMP) demonstrates therapeutic potential for endometriosis by targeting key fibrotic and cellular transition pathways.
- TMP's favorable safety profile suggests it is a promising candidate for developing novel, non-hormonal endometriosis therapies.
